http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 22 Jun 2026 08:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Press+Releases/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kwfTCKOst8DdfboCFI9Kx-2XuyPV13cxDY9X_WrLf_Zc7owl-SKQ86B64pSsCYJU8V8UCxPzLozAQ9WxblAwk8JppsJviOU2Uv6Odz0HdZEMUaF8GSn2BxlZI5magbJUTzNKwfsR_qjMJJ2LRJF2E1UUT_RL5ezXziD5vgiL0Cz-V67oWJC0erB81seDFc3WxNHB2kJhsj1h1BA8OXE2qAL9bYb24W_T5sQEo7r2Kfei-W72RPceVqZp2w4JN4sk25BOTlyPYnU6Zcc8bTfqgTknKLrD7ycfsBzv6lHj_w2AdM-YuiQxGmG5HyuxeN9K" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is <a href="https://www.globenewswire.com/Tracker?data=Hm8nwRaHtVPrBFWBlgYBHjc39SyWZM78HOyiBJynTPScEv6lp7qrqX8Ansc3CQYIJo1TRMcaQSUkaK2YvP5ztA==" rel="nofollow" target="_blank">expanding</a> rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an <a href="https://www.globenewswire.com/Tracker?data=8-gzz0thi2gKKiTrpIX4EQEddADgjXjYQ2ZIFtfXfZNNt0ZVSYzVHQprCL8PfnM1gaDrumlDtPR3yHL8GFMOtA==" rel="nofollow" target="_blank">estimated</a> $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and <a href="https://www.globenewswire.com/Tracker?data=TufnlcuEzVbz6kcqSCUtH5MlIXGVNrIT6tWVoM1YRwe4qn7BR-yhUFxZtpGkptUOVZEDJ5wExTqAJgF7ZCKj0ikxGqLMzaO6S8lpDoBzIGY=" rel="nofollow" target="_blank">precision medicine</a> markets are projected to climb to roughly $750 billion http://www.streetinsider.com/Globe+Newswire/Next-Generation+DNA+Repair+Therapies+Open+New+Frontiers+in+Oncology/26670383.html Mon, 22 Jun 2026 08:30:00 -0400 APRE APRE AZN AZN BOLD BOLD FHTX FHTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Grissinger+Michael/26661360.html si-local-file:///var/storage/secattach/20260617/26661360.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Grissinger+Michael/26661360.html Wed, 17 Jun 2026 19:10:00 -0400 APRE O.42040581 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Grissinger+Michael/26661360.html si-local-file:///var/storage/secattach/20260617/26661360.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Grissinger+Michael/26661360.html Wed, 17 Jun 2026 19:10:00 -0400 APRE O.42040581 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Gruia+Gabriela/26661357.html si-local-file:///var/storage/secattach/20260617/26661357.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Gruia+Gabriela/26661357.html Wed, 17 Jun 2026 19:08:00 -0400 APRE O.42040581 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Gruia+Gabriela/26661357.html si-local-file:///var/storage/secattach/20260617/26661357.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Gruia+Gabriela/26661357.html Wed, 17 Jun 2026 19:08:00 -0400 APRE O.42040581 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Peters+Richard/26661354.html si-local-file:///var/storage/secattach/20260617/26661354.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Peters+Richard/26661354.html Wed, 17 Jun 2026 19:07:00 -0400 APRE O.42040581 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Peters+Richard/26661354.html si-local-file:///var/storage/secattach/20260617/26661354.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+Peters+Richard/26661354.html Wed, 17 Jun 2026 19:07:00 -0400 APRE O.42040581 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+HENNEMAN+JOHN+B+III/26661352.html si-local-file:///var/storage/secattach/20260617/26661352.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+HENNEMAN+JOHN+B+III/26661352.html Wed, 17 Jun 2026 19:06:00 -0400 APRE O.42040581 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+HENNEMAN+JOHN+B+III/26661352.html si-local-file:///var/storage/secattach/20260617/26661352.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+HENNEMAN+JOHN+B+III/26661352.html Wed, 17 Jun 2026 19:06:00 -0400 APRE O.42040581 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+BIZZARI+JEAN-PIERRE/26661344.html si-local-file:///var/storage/secattach/20260617/26661344.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aprea+Therapeutics%2C+Inc.++For%3A+Jun+16++Filed+by%3A+BIZZARI+JEAN-PIERRE/26661344.html Wed, 17 Jun 2026 19:05:00 -0400 APRE O.42040581